placeholder
Importance
62
Trust
71
Urgency
30
COMMERCIAL
Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act - BioSpace
Eli Lilly's CEO made critical comments about rivals AbbVie and Pfizer in the race to develop amylin drugs for weight loss. Amylin is a hormone that works differently than current GLP-1 weight-loss medications.
Analysis
Lilly's CEO is talking up its lead in amylin drugs, the next wave of weight-loss shots. Pfizer and AbbVie are also chasing this market.
- Lilly CEO made critical comments about AbbVie and Pfizer amylin programs
- Race centers on amylin drugs as the next step beyond GLP-1 weight-loss meds
BioSpace1mo
Read